NASDAQ
2.01USD
+0.03 (+1.52%)
We have scored 9 news catalysts on Neuronetics, Inc. (STIM) over the past 12 months. The biggest single-day move next to one of them came Jul 20, 2026, when STIM closed +24.7%: “Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes”. Coverage across the window leans positive (average ticker sentiment +0.42). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
153.2M
P/E
—
EPS
—
Beta
1.20
52W range
0.8-3.44
Day range
1.97–2.02
Open
1.97
Prev close
1.98
Volume
327K
Avg volume
1.8M
Dividend
0.00
IPO
2018-06-28
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Neuronetics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for STIM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
